Edge (Constantine) devotes issue to Triple Negatives

Options
saluki
saluki Member Posts: 2,287
edited June 2014 in Triple-Negative Breast Cancer
Edge (Constantine) devotes issue to Triple Negatives
· Share on FacebookShare on Twitter

Comments

  • saluki
    saluki Member Posts: 2,287
    edited October 2007

    Some of you may or may not be familiar with Edge (Constantine).  He used to come on and occasionally contribute.

    He was the first to bring to our attention The David Flockart studies about tamoxifen,  SSRI's and the cytochrome P450 enzyme.  He has a site that compiles all the latest research on Breast Cancer.  

    Anyway, he started putting out a digest this year and the latest issue is exclucively about triple negatives.  I thought you may be interested.

    http://bcwatchdigest.evidencewatch.com/ 

    · Share on FacebookShare on Twitter
  • Anonymous
    Anonymous Member Posts: 1,376
    edited May 2008

    Thanks for posting this link Saluki!!!

    · Share on FacebookShare on Twitter
  • nosurrender
    nosurrender Member Posts: 2,019
    edited October 2007

    Hey Susie,

    Thanks for linking Edge's Newsletter here. He has been an enormous help to me and I am so grateful to him and to his unbelievable generosity.

    He compiled the info for his newsletter into a special report for my site and added info that isn't in the newsletter pertaining to the conferences he recently attended and a sneak peak at what will be reported at the San Antonio Breast Cancer Symposium.

    This is what he posted:

    "That version [newsletter] also contains some additional tutorial-type material on DNA damage and PARP inhibitors, and briefly describes the methodology of the review, while this special invited presentation for the No Surrender forum has additional material relating to recent conference discussions plus some hints at findings to be reported at the upcoming SABCS 2007 this December.  "

    If you want to see that version go HERE or HERE.

    Thanks again, he really is the best!

    love,

    g 

    · Share on FacebookShare on Twitter

Categories